StocksRunner logo
mail
search
 
menu
 
AbbVie
$189.26
-1.12%
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
 
 

ABBV

 

AbbVie

$189.26

 
-$2.14 | -1.12%
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
52W High
$ 218.66
 
 
MKT CAP
$ 334.31B
 
52W Low
$ 163.81
 
 
VOL
$ 5.33M
 
P/E Ratio
80.7
 
 
AVG VOL
$ 6.22M
 
RSI
 
 
TREND
 
 
 

Chart

 
 

$186.98   (+1.22%)

$172.99   (+9.41%)

$210.75   (-10.20%)

$181.94   (+4.02%)

 
 
1year
6month
3month
1month
 
ABBV Latest Analysis +
 
 
 
StocksRunner

Explore our ABBV Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored ABBV Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our ABBV Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
StocksRunner
 
 
StocksRunner Overview
 
StocksRunner Trending
 
StocksRunner Screener
 
StocksRunner Insights
 
StocksRunner Top Rated
 
StocksRunner Momentum
 
StocksRunner Earnings
mail
 
 

ABBV

 

AbbVie

 
 

Current Price

 

$189.26

 
-$2.14 | -1.12%
 
ABBV Rating Score

Buy

 
52W High
$ 218.66
 
 
MKT CAP
$ 334.31B
 
52W Low
$ 163.81
 
 
VOL
$ 5.33M
 
P/E Ratio
80.7
 
 
AVG VOL
$ 6.22M
 
RSI
 
 
TREND
 
 
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
 
 
 
 
 
 

ABBV Stock Rating

 
lock  Login to view AbbVie (ABBV) recommendation from the last 90 days from financial news and social media.
 

Chart

 
 

$186.98   (+1.22%)

$172.99   (+9.41%)

$210.75   (-10.20%)

$181.94   (+4.02%)

 
 
1year
6month
3month
1month
 
 
 
 
 

ABBV Latest Analysis

 
 
 

Dementia Associated with Alzheimers Disease Drug Development Surges with 180 Companies Pushing New Therapeutic Frontiers | DelveInsight. Dementia Associated with Alzheimer'.s Disease Drug Development Surges with 180 Companies Pushing New Therapeutic Frontiers |. DelveInsightDementia associated with Alzheimer'.s disease is a progressive neurodegenerative condition characterized by memory loss cognitive decline and impaired daily functioning. The growing aging population worldwide is l

 

Thu Jul 17, 2025

$191.55 | +0.44%
 
Activity

AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing. The latest trading day saw AbbVie (ABBV) settling at $190.58 representing a 2.25% change from its previous close.

 

Wed Jul 16, 2025

$190.58 | +2.34%
 
Momentum

Looking Into AbbVies Recent Short Interest. ) short percent of float has risen 8.43% since its last report. The company recently reported that it has Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price ...

 

Wed Jul 16, 2025

$190.58 | +2.34%
 
Momentum

Heres How to Play AbbVie Stock as it Reaches Golden Cross . ABBV hits a ish golden cross as Skyrizi and Rinvoq drive growth offsetting Humira losses and aesthetic headwinds.

 

Tue Jul 15, 2025

$186.25 | -1.91%
 
Potential
Technical

Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight. Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements |. DelveInsight The Waldenstrom macroglobulinemia market is witnessing steady growth driven by advances in targeted therapies particularly BTK inhibitors like IMBRUVICA and BRUKINSA. Rising awareness improved diagnostic techniques and increasing clinical trial activity ar

 

Mon Jul 14, 2025

$191.44 | -0.46%
 
Activity

Ex-Dividend Reminder: Buckle AbbVie and PNC Financial Services Group. Looking at the universe of stocks we cover at Dividend Channel on 7/15/25 Buckle Inc. (Symbol: BKE) AbbVie Inc (Symbol: ABBV) and PNC Financial Services Group (Symbol: PNC) will all trade ex-dividend for their respective upcoming dividends. Buckle Inc. will pay its quarter

 

Fri Jul 11, 2025

$192.45 | -1.31%
 
Activity

Boeing Joby Aviation Oracle And A Health Care Stock: CNBCs Final Trades. The investment landscape is shifting as companies across various sectors demonstrate resilience and innovation prompting investors to reassess their portfolios.On CNBC'.s “.Halftime Report Final Trades”. ) can break above $197 it marches towards .According to recent news IGI Therapeutics SA a wholly owned subsidiary of Ichnos Glenmark Innovation Inc. and AbbVie announced on Thursday an exclusive licensing agre

 

Fri Jul 11, 2025

$192.45 | -1.31%
 
Activity

Glenmark Pharma shares rally 14% on AbbVie boost. analysts hike targets to Rs 2800 . Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug ISB 2001. Analysts see up to 29% more upside with technical experts advising a buy on dips strategy. The stock broke out from a key gap zone and brokerages like Motilal Oswal see targets up to Rs 2800.

 

Fri Jul 11, 2025

$192.45 | -1.31%
 
Activity
Momentum
Potential

Why Is AbbVie Stock Trading Higher On Thursday?. ) on Thursday announced an exclusive licensing agreement for IGI’.s lead investigational asset ISB 2001 developed using IGI’.s proprietary BEAT protein platform for .“.Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper more durable responses by engaging multiple targets simultaneously”. said AbbVie will receive exclusive rights to develop manufacture

 

Thu Jul 10, 2025

$195.00 | +2.36%
 
Activity
Momentum

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001 a First-in-Class CD38×BCMA×CD3 Trispecific Antibody. ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NEW YORK and NORTH CHICAGO Ill. July 10 2025 /PRNewswire/ -- IGI Therapeutics SA a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc. (IGI) and...

 

Thu Jul 10, 2025

$195.00 | +2.36%
 
Activity
Activity

 
 
 
 
 
StocksRunner

Discover ABBV Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of ABBV. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our ABBV Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

ABBV Stock trends

ABBV Stock performance

ABBV Stock analysis

ABBV investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 

UnAlert ABBV Runner Alarm

Real-time signals powered by data
×

Price-Based

Triggers when the stock breaks through a known resistance level
 
Triggers when the stock drops below a key support level
 
Notifies if the stock moves up/down by a set percentage (e.g. ±5%)
 
Alerts when the stock hits a new high or low
 
Signals proximity to long-term highs or lows (e.g. within 5%)
 

Technical Indicator (Pro Plan)

Volume spikes 2x–3x above average. Indicates strong buying/selling pressure
 
Tracks large intraday swings, signaling potential opportunities or risk
 
Signals potential trend reversals or continuations
 
Long-term bullish/bearish trend signals from MA crossovers
 
RSI above 70 or below 30 to identify possible reversals
 
Signals momentum shifts
 

Fundamental (Master Plan)

Upcoming or just-released earnings reports
 
Alerts after results compared to expectations
 
Changes in rating or target price
 
New or changed dividends
 
Large trades by company insiders
 
M&A, lawsuits, product launches, etc
 
High volume/open interest in call/put contracts
 
Surge in mentions or sentiment shifts
 

 
 
Post ×
 
0/666
joker
 
 
 
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing ABBV

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

 
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing ABBV

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.